Fuda Cancer Hospital
Fuda Cancer Hospital
China, Cantão
| China | Turquia | Áustria | |
| Quimioterapia para cancro da mama | de $14,800 | de $1,200 | de $15,000 |
| Quimioterapia Intraperitoneal Hipertérmica (HIPEC) | de $22,500 | de $22,500 | de $40,000 |
| Colectomia (resseção do intestino grosso) | de $16,500 | de $6,912 | de $22,000 |
A Bookimed não adiciona taxas extras aos preços de tratamento de Cancro do cólon em estádio 4. As tarifas vêm das listas oficiais de preços das clínicas. O pagamento é feito diretamente na clínica na chegada ao país.
A Bookimed está comprometida com sua segurança. Trabalha apenas com instituições que mantêm altos padrões internacionais no tratamento de Cancro do cólon em estádio 4 e têm as licenças necessárias para atender pacientes internacionais em todo o mundo.
A Bookimed oferece assistência gratuita de especialistas. Um coordenador médico pessoal apoia antes, durante e após o tratamento, solucionando problemas. Nunca está sozinho em sua jornada de tratamento de Cancro do cólon em estádio 4.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
Chinese systemic therapies for stage 4 colon cancer follow Chinese Society of Clinical Oncology guidelines. Treatment relies on genetic biomarkers like KRAS, NRAS, and BRAF status. Standard protocols combine chemotherapy backbones with targeted monoclonal antibodies or immunotherapy for microsatellite instability-high tumors.
Bookimed Expert Insight: Specialized facilities like Fuda Cancer Hospital combine systemic chemotherapy with unique minimally invasive technologies. Their approach often integrates vascular interventional therapy or cryosurgery for liver metastases. This multi-modal strategy serves over 30,000 international patients seeking options beyond standard drug protocols.
Patient Consensus: Patients emphasize the need to request comprehensive biomarker testing early. They often note that top-tier centers are much more likely to offer modern immunotherapy options than smaller local hospitals.
Chinese oncology centers utilize advanced ablative and interventional technologies to manage inoperable stage 4 colon cancer. Key treatments include NanoKnife, cryosurgery, and microwave hyperthermia combined with precision radiotherapy like SBRT. These minimally invasive tools target metastases in the liver or lungs to extend survival.
Bookimed Expert Insight: While most global centers follow standard chemotherapy protocols, Fuda Cancer Hospital in Guangzhou provides over 10 different minimally invasive therapies. Our data shows they often use these as alternatives or supplements to traditional chemo for advanced cases. This specialized focus has attracted over 30,000 international patients seeking local tumor control for late-stage malignancies.
Patient Consensus: Patients value these procedures for rapid symptom relief, specifically mentioning bowel stenting to avoid emergency surgery. Many note that having an attendant stay in the hospital room provides essential emotional support during treatment.
Immunotherapy is widely accessible for dMMR or MSI-H stage 4 colon cancer in China. The National Medical Products Administration (NMPA) approves pembrolizumab and domestic PD-1 inhibitors like tislelizumab. These therapies are clinically recommended as standard treatments by the Chinese Society of Clinical Oncology. Clinical status is verified using NMPA-approved diagnostic kits.
Bookimed Expert Insight: While international drugs like pembrolizumab are available, domestic PD-1 inhibitors like tislelizumab are often preferred in China due to their inclusion in the National Reimbursement Drug List. These domestic options maintain high efficacy while significantly reducing out-of-pocket expenses compared to imported therapies. Facilities like Fuda Cancer Hospital in Guangzhou serve over 30,000 international patients and specialize in combining these immunotherapies with minimally invasive procedures to manage advanced stages.
Patient Consensus: Patients note that MSI-H status can lead to dramatic tumor shrinkage and emphasize getting biomarker testing early to potentially avoid standard chemotherapy. Those treated in major Chinese cities appreciate that attendants can stay in the ward throughout the treatment process.
China integrates Traditional Chinese Medicine (TCM) as a supportive framework alongside standard Western oncology for stage 4 colon cancer. This dual-system model uses herbal decoctions and acupuncture to manage chemotherapy side effects. It focuses on improving quality of life and immune function in JCI-accredited facilities.
Bookimed Expert Insight: Clinical data from specialized centers like Fuda Cancer Hospital in Guangzhou reveals a strategic shift. While they are famous for technologies like cryosurgery and NanoKnife, they use TCM specifically to help patients qualify for these procedures. By using Qi-nourishing herbs to stabilize blood counts, doctors ensure patients meet the physical requirements for intensive, minimally invasive interventions.
Patient Consensus: Patients note that having a caregiver stay in the ward is a major benefit in Chinese hospitals. They emphasize the importance of using hospital-based TCM rather than outside remedies to ensure safety during intensive treatments.
China's top oncology centers in Guangzhou, Beijing, and Shanghai receive the most advanced colon cancer referrals. Leading hospitals like Fuda Cancer Hospital hold JCI accreditation. They specialize in treating stage four disease using NanoKnife, cryosurgery, and hyperthermic intraperitoneal chemotherapy (HIPEC) for complex cases.
Bookimed Expert Insight: Patient volume data shows that Fuda Cancer Hospital is the primary hub for global referrals in China. While many general hospitals treat cancer, Fuda specializes exclusively in late-stage oncology. Their 400-bed capacity is dedicated to minimally invasive therapies like vascular interventional treatment. This focus makes them a preferred choice for patients from over 100 nations.
Patient Consensus: Patients value the ability for family members to stay in the ward during treatment. They emphasize that while Russian clinics may decline complex cases, Chinese specialists offer hope and professional care.